ClinicalTrials.gg
Not yet recruitingNCT07761169Updated Aug 12, 2026

Randomized Controlled Trial of the SurgDiff Model for Predicting Surgical Difficulty to Help Choose Approach in Mid-Low Rectal Cancer

An interventional study of AI-assisted decision-making in Rectal Cancer, sponsored by Peking Union Medical College Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital — 9 open to participants now, 10 under way, none of them phase 3. Rectal Neoplasms · Peking Union Medical College Hospital.

Planned enrollment
8th of 11
68 · median 150
Started
2026
with 1 other
No phase
7 of 13
5 open now
Registered
12th of 13
by date

Among the 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 12th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 587 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

9 of the 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

This study aims to investigate the feasibility of utilizing the SurgDiff surgical difficulty prediction model to assist surgeons in formulating precise surgical plans.

03

Conditions studied

  • Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pathological examination confirmed a diagnosis of rectal adenocarcinoma; radical surgery is recommended.
  2. The inferior border of the tumor is ≥1 cm from the dentate line and ≤7 cm from the anal verge;
  3. Preoperative staging was assessed in a stage of c/ycT1-3N0-2M0;
  4. The cardiac, pulmonary, hepatic, renal, and other organ functions are adequate, and the patient can tolerate laparoscopic surgery.

Exclusion criteria

Exclusion Criteria:

  1. Intraoperative exploration is unable to achieve R0 resection or preservation of the anus;
  2. Lateral lymph node dissection is required;
  3. Patients with a history of severe mental illness, immune disorders, or those taking hormonal medications;
  4. Any other circumstances in which the investigator deems it inappropriate for inclusion.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    experimental group

    The SurgDiff model performs a difficulty assessment based on the patient's preoperative MRI scans and clinical data, thereby assisting the surgeon in formulating the surgical plan.

    Procedure: AI-assisted decision-making

  • No intervention
    control group

    The surgeon selects the surgical approach and performs the procedure

Interventions

  • ProcedureAI-assisted decision-making

    The SurgDiff model performs a difficulty assessment based on the patient's preoperative MRI scans and clinical data, thereby assisting the surgeon in formulating the surgical plan

06

What researchers measure

Primary outcomes

  1. Mesorectal incomplete rate

    Time frame: 2 weeks after surgery

Secondary outcomes

  1. Operative conversion rate

    Defined as the proportion of cases where laparoscopic total mesoresection (laTME) was converted to open total mesoresection (taTME), or where taTME was converted back to laTME, or where conversion occurred to an open surgical approach during the procedure.

    Time frame: during the surgery

  2. Positive resection margin rate

    defined as the presence of cancer cells on the distal rectal resection margin

    Time frame: 2 weeks after surgery

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Sep 2027, 12 months later.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 12 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2026
First posted
Aug 12, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 30, 2030
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07761169
Responsible party
XIAO Yi, MD (Xiao Yi, Peking Union Medical College Hospital) — Principal investigator
First posted
Aug 12, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Aug 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion